StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)

StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a report issued on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Up 6.0 %

NASDAQ:AKTX opened at $3.16 on Monday. The company has a 50-day moving average of $3.56 and a 200-day moving average of $2.60. Akari Therapeutics has a 52 week low of $1.08 and a 52 week high of $4.40.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.